HE, YUNSHENG,LEISNER, CHRISTIAN,WALD, MICHAEL,WEISSGERBER, GEORGES
申请号：
CA3032790
公开号：
CA3032790A1
申请日:
2017.06.19
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFa antagonist, e.g., a TNFa antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFa antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFa antagonist, e.g., a TNFa antibody, such as LME636.
